Benefits
Kidney Stone Prevention (FDA-Approved)
Potassium citrate is FDA-APPROVED (Urocit-K® prescription) for prevention of calcium oxalate, uric acid, and cystine kidney stones. Mechanism: raises urinary citrate (which inhibits calcium oxalate crystallization) and urinary pH (which prevents uric acid stones). Standard urology care for recurrent stone-formers.
Urinary Alkalinizer
Citrate metabolizes to bicarbonate — raises urinary pH. Used for: gout (uric acid stones), cystinuria (cystine stones), and adjunct in some chemotherapy protocols (urinary alkalinization to reduce kidney damage).
Bone Health (Modest Evidence)
Potassium citrate may modestly support bone health by buffering metabolic acid load (typical Western diets are net-acid-producing). Some evidence for reduced bone resorption markers; effect modest. Whole-diet approach (DASH, Mediterranean) more impactful than single supplement.
Blood Pressure Modest Reduction
Adequate potassium intake reduces blood pressure; potassium citrate provides supplemental potassium without GI ulceration risk of potassium chloride. Modest BP reduction comparable to other potassium sources.
Lower GI Toxicity than Potassium Chloride
Potassium chloride tablets can cause GI ulceration if not adequately diluted. Potassium citrate has less GI toxicity — preferred for patients sensitive to chloride forms or with prior GI issues.
Mechanism of action
Citrate to Bicarbonate Conversion
Absorbed citrate is metabolized in liver to bicarbonate — neutralizes metabolic acid load and raises urinary pH. Urinary citrate excretion increases, providing the stone-prevention mechanism.
Calcium Oxalate Stone Inhibition
Urinary citrate binds calcium and reduces calcium oxalate supersaturation — major mechanism for calcium oxalate stone prevention. Hypocitraturia is a major risk factor for these stones.
Urinary pH Elevation
Raised urinary pH prevents uric acid stone formation (uric acid is more soluble at higher pH) and cystine stone formation. Targeted pH 6.5-7.0 for stone prevention.
Acid-Base Buffering
Bicarbonate generation buffers chronic mild metabolic acidosis from typical Western diets — proposed mechanism for bone-sparing effects.
Clinical trials
Multiple RCTs of potassium citrate (30-60 mEq/day) for prevention of recurrent calcium oxalate kidney stones.
Recurrent calcium oxalate stone-formers.
Potassium citrate significantly reduces recurrent stone formation vs placebo. Standard urology care; recommended in AUA stone prevention guidelines.
Meta-analysis of potassium citrate effects on bone turnover markers and bone density.
Pooled across bone health RCTs.
Potassium citrate modestly reduces bone resorption markers and may slow bone loss. Effect sizes modest. Bone density changes inconsistent across trials. Adjunctive role only.
About this ingredient
Potassium citrate is potassium combined with citric acid — distinguished from potassium chloride (the most common potassium supplement) by its ALKALINIZING EFFECT and FDA-APPROVED USE for kidney stone prevention (Urocit-K® prescription). KEY DIFFERENCES from potassium chloride: (1) Citrate metabolizes to BICARBONATE — raises urinary pH and citrate; (2) Less GI ulceration risk; (3) Pharmaceutical stone-prevention indication. PHARMACEUTICAL FORM: Urocit-K® (Mission Pharmacal) is FDA-approved for: calcium oxalate stones with hypocitraturia, uric acid stones (with or without calcium oxalate), and cystinuria. Prescription only for therapeutic doses (30-90 mEq/day). NUTRITIONAL FORM: lower-dose potassium citrate is OTC for general potassium supplementation.
EVIDENCE-BASED USES: (1) KIDNEY STONE PREVENTION (FDA-approved; AUA-recommended); (2) Urinary alkalinization (gout, cystinuria, chemotherapy adjunct); (3) Blood pressure modest reduction; (4) Modest bone-sparing effect via metabolic acid buffering; (5) General potassium supplementation.
CRITICAL CAUTIONS: (1) HYPERKALEMIA RISK — POTENTIALLY FATAL; especially with ACE inhibitors, ARBs, aldosterone antagonists (spironolactone), potassium-sparing diuretics (amiloride, triamterene), trimethoprim, NSAIDs; monitor potassium with any combination; (2) CHRONIC KIDNEY DISEASE — kidney's reduced potassium excretion makes hyperkalemia more likely; AVOID supplemental potassium in advanced CKD without nephrology supervision; (3) ADDISON'S DISEASE / aldosterone deficiency — hyperkalemia risk; (4) Pharmaceutical doses (30-90 mEq/day for stone prevention) MUST be supervised; not self-prescribed; (5) PILL BURDEN at therapeutic doses — multiple large pills; adherence challenge; (6) DRUG INTERACTIONS — chelation with antibiotics; aluminum absorption increase in CKD/dialysis; (7) PREGNANCY/LACTATION — generally safe at typical nutritional doses; pharmaceutical doses require obstetric supervision; (8) DIET — most healthy adults can meet potassium needs through food (bananas, potatoes, beans, leafy greens); supplementation rarely needed except for hypokalemia or stone prevention; (9) THE 4,700 mg/day RDA — most Americans don't meet potassium RDA; whole-food approaches (DASH diet) better than supplementation; (10) STONE PREVENTION — urology supervision recommended; baseline 24-hour urine collection; periodic monitoring of urinary citrate, pH, calcium, oxalate.